We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Below we will list the departments and units that form part of Vall d’Hebron Hospital and the main diseases that we treat. We will also make recommendations based on advice backed up by scientific evidence that has been shown to be effective in guaranteeing well-being and quality of life.
Vols saber com serà la teva estada a l’Hospital Universitari Vall d’Hebron? Aquí trobaràs tota la informació.
Speaker: Marta Barber Servera, predoctoral Researcher, Cancer Laboratory/Biomedical Research Group in Urology (VHIR).
Aurora Borealis (BORA) is the major activator of the mitotic kinase polo-like kinase 1 (PLK1). Both proteins are known to have an oncogenic role in the tumorigenesis and progression of ovarian cancer (OC). OC is a very aggressive tumor type usually diagnosed at advanced stages where the survival is very low and there are not targeted therapies. Our project aims to decipher the mechanisms by which BORA enhances OC aggressiveness, and also to validate BORA as a potential therapeutic target for OC. Our results indicate that BORA overexpression increases, through PLK1 activation, the expression of genes involved in epithelial-mesenchymal transition (EMT), resulting in higher migration and invasive capacities in vitro and faster metastasis formation in vivo. By contrast, BORA downregulation reduces OC cell viability in vitro and ex vivo, both as a single treatment and in combination with the standard of care (cisplatin/paclitaxel). Altogether, our results uncovered a potential new role of BORA in OC metastasis through the induction of EMT. Moreover, we demonstrated that targeting BORA with RNA-based nanotherapies reduces OC cell viability, providing a potential therapeutic opportunity for OC management.
Marta Barber Servera, predoctoral Researcher in Cell Cycle and Cancer Laboratory/Biomedical Research Group in Urology (VHIR), led by Dr. Juan Morote and Dra. Anna Santamaria (thesis supervisor). Graduated in Biomedical Science by the Universitat Autonoma de Barcelona and in the Translational Biomedical Research Master (VHIR).
Host: Dr. Olga Méndez Fernández, Postdoctoral researcher Biomedical Research in Urology (VHIR)
Select the newsletter you want to receive:
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Hospital Universitari Vall d'Hebron - Institut Català de la Salut. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.